Stockreport

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC [Yahoo! Finance]

Protara Therapeutics, Inc.  (TARA) 
PDF TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC program TARA-002 demonstrated a favorable safety and toler [Read more]